A Phase 2a, Open-Label Biomarker Study of IC14 for the Treatment of Patients With Rapidly Progressive Amyotrophic Lateral Sclerosis(ALS)

Trial Profile

A Phase 2a, Open-Label Biomarker Study of IC14 for the Treatment of Patients With Rapidly Progressive Amyotrophic Lateral Sclerosis(ALS)

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Apr 2018

At a glance

  • Drugs IC 14 (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Biomarker; Therapeutic Use
  • Sponsors Implicit Bioscience
  • Most Recent Events

    • 28 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top